Institut Bergonié

This study tests whether freezing a tumor (cryoablation) plus standard immunotherapy and chemotherapy helps people with advanced lung cancer live longer. About 214 participants will be randomly assigned to receive either the standard drug combination alone or with the freezing tr…

This study tests two drugs, pembrolizumab and cabozantinib, together in people with advanced sarcomas (cancers of the soft tissue or bone) that have not responded to standard treatments. The goal is to see if the combination can stop or shrink tumors for at least 6 months. About …

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This study tests whether high-intensity focused ultrasound (HIFU) can destroy breast tumors without surgery. Fifteen women with small, early-stage breast cancers will receive HIFU before their planned surgery. The main goal is to see if the ultrasound completely kills the tumor c…

This Phase 3 trial is testing whether adding three extra cycles of chemotherapy before surgery can help prevent cancer spread in people with high-risk soft-tissue sarcoma. About 351 participants will be randomly assigned to standard treatment or standard treatment plus extra chem…

This study is for people with a certain type of prostate cancer that is not too advanced but has some higher-risk features. It tests whether adding a short course of the drug darolutamide to standard radiation therapy can lower PSA levels to a very low target (0.1 ng/mL or less) …

This observational study is analyzing tumor and blood samples from 50 people with pancreatic cancer to measure levels of certain proteins called convertases. Researchers want to see if these protein levels are linked to immune cells in the tumor, which could help predict how the …

This study looks at how much radiation reaches tumors and healthy organs during a treatment called 177Lu-PSMA-617 for advanced prostate cancer that has spread. Researchers want to see if the radiation dose can predict how well the treatment works and what side effects might occur…

This study is testing whether artificial intelligence can help doctors better classify and predict the behavior of rare smooth muscle tumors of the uterus, including those that are hard to diagnose (called STUMP). Researchers will train AI models on digital images of tumor tissue…

This study looks at whether a genetic test called CINSARC can predict how well chemotherapy works in people with soft-tissue sarcoma. Researchers will collect tumor and blood samples from 205 participants before they receive standard chemotherapy and surgery. The goal is to see i…

This study is testing whether regular blood tests that look for tumor DNA (called liquid biopsy) can help doctors make better treatment decisions for people with advanced colorectal or lung cancer. About 332 participants will be randomly assigned to either receive standard imagin…

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…

This study is looking at whether tracking tiny bits of tumor DNA in the blood can help predict if breast cancer will come back after chemotherapy and surgery. Researchers will take blood samples from 180 people every 6 months for 5 years. The goal is to see if these DNA clues can…

This study collects and analyzes data from 30,000 breast cancer patients treated at Institut Bergonié since the 1990s. Researchers aim to track survival, assess treatment practices, and search for factors that predict outcomes. No new treatments are being tested; instead, the goa…

This study is building a huge national database in France to collect medical and biological information from up to 150,000 people with sarcoma. Researchers will use this data to describe how sarcomas are treated in real-world practice and what factors affect patient outcomes. No …